Brain Disease Comprehensive Study by Type (Brain Cancer, Alzheimer Disease, Alcoholism, Amnesia, Epilepsy, Meningitis, Others), Distribution Channel (Hospitals Pharmacy, Online Pharmacy, Offline Pharmacy), Diagnosis Type (CT Scan, MRI, PET-CT Scan, Molecular Testing, EEG, Others), Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy) Players and Region - Global Market Outlook to 2026

Brain Disease Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Brain disease is a type of central nervous system diseases. It refers to disabilities that affect the brain. There are various disability condition present in the brain disease such as brain deterioration, neurodegenerative diseases such as Alzheimer’s, Huntington’s disease and others. There are various symptoms of brain diseases such as headache, memory loss, tremors, increased reflexes, slurred speech, paralysis, and inability to concentrate among others. Surgery, radiation therapy, targeted therapy, chemotherapy and immunotherapy are the various treatment types used for brain disease.This growth is primarily driven by Increasing Awareness of Brain Diseases and Their Treatments and Reducing Prices of Some Brain Disease Treatment.

Globally, a noticeable market trend is evident Rising Government Support for Improving Healthcare System . Major Players, such as Pfizer Inc. (United States), Eli Lilly (United States), F. Hoffmann La Roche AG (Switzerland), GE Healthcare (United States), Abbvie Inc. (United States), AC Immune SA (Switzerland), Allergan PLC (Ireland), Merck & Co (United States), Novartis AG (Switzerland) and AstraZeneca plc (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 23rd October 2018, Pfizer a leading American pharmaceutical corporation headquartered in New York City and Bain Capital has came together to create new neuroscience-focused company.
On 24th November 2018, GE Healthcare has launched new applications and smart devices built on Edison. AIRx* is an AI-based, automated workflow device for MRI brain scanning designed to rise steadiness and productivity. On 4th January 2018, Pfizer has launched iTeos Therapeutics regained rights to its Phase I brain cancer drug.

Market Drivers
  • Increasing Awareness of Brain Diseases and Their Treatments
  • Reducing Prices of Some Brain Disease Treatment

Market Trend
  • Rising Government Support for Improving Healthcare System
  • Technological Advancement Related to Brain cancer

Restraints
  • Contrary Effects with the Medications
  • Unfavorable Compensation Policies

Opportunities
Increasing Health Care Expenditure in Developing Country and Escalating Therapeutic Applications of Brain Monitoring Devices

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Brain Disease Study Sheds Light on
— The Brain Disease Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Brain Disease industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Brain Disease industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Brain Cancer
  • Alzheimer Disease
  • Alcoholism
  • Amnesia
  • Epilepsy
  • Meningitis
  • Others
By Distribution Channel
  • Hospitals Pharmacy
  • Online Pharmacy
  • Offline Pharmacy

By Diagnosis Type
  • CT Scan
  • MRI
  • PET-CT Scan
  • Molecular Testing
  • EEG
  • Others

By Treatment Type
  • Surgery
  • Radiation Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness of Brain Diseases and Their Treatments
      • 3.2.2. Reducing Prices of Some Brain Disease Treatment
    • 3.3. Market Trends
      • 3.3.1. Rising Government Support for Improving Healthcare System
      • 3.3.2. Technological Advancement Related to Brain cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brain Disease, by Type, Distribution Channel, Diagnosis Type, Treatment Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Brain Disease (Value)
      • 5.2.1. Global Brain Disease by: Type (Value)
        • 5.2.1.1. Brain Cancer
        • 5.2.1.2. Alzheimer Disease
        • 5.2.1.3. Alcoholism
        • 5.2.1.4. Amnesia
        • 5.2.1.5. Epilepsy
        • 5.2.1.6. Meningitis
        • 5.2.1.7. Others
      • 5.2.2. Global Brain Disease by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals Pharmacy
        • 5.2.2.2. Online Pharmacy
        • 5.2.2.3. Offline Pharmacy
      • 5.2.3. Global Brain Disease by: Diagnosis Type (Value)
        • 5.2.3.1. CT Scan
        • 5.2.3.2. MRI
        • 5.2.3.3. PET-CT Scan
        • 5.2.3.4. Molecular Testing
        • 5.2.3.5. EEG
        • 5.2.3.6. Others
      • 5.2.4. Global Brain Disease by: Treatment Type (Value)
        • 5.2.4.1. Surgery
        • 5.2.4.2. Radiation Therapy
        • 5.2.4.3. Targeted Therapy
        • 5.2.4.4. Chemotherapy
        • 5.2.4.5. Immunotherapy
      • 5.2.5. Global Brain Disease Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Brain Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann La Roche AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GE Healthcare (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbvie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AC Immune SA (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergan PLC (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Brain Disease Sale, by Type, Distribution Channel, Diagnosis Type, Treatment Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Brain Disease (Value)
      • 7.2.1. Global Brain Disease by: Type (Value)
        • 7.2.1.1. Brain Cancer
        • 7.2.1.2. Alzheimer Disease
        • 7.2.1.3. Alcoholism
        • 7.2.1.4. Amnesia
        • 7.2.1.5. Epilepsy
        • 7.2.1.6. Meningitis
        • 7.2.1.7. Others
      • 7.2.2. Global Brain Disease by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals Pharmacy
        • 7.2.2.2. Online Pharmacy
        • 7.2.2.3. Offline Pharmacy
      • 7.2.3. Global Brain Disease by: Diagnosis Type (Value)
        • 7.2.3.1. CT Scan
        • 7.2.3.2. MRI
        • 7.2.3.3. PET-CT Scan
        • 7.2.3.4. Molecular Testing
        • 7.2.3.5. EEG
        • 7.2.3.6. Others
      • 7.2.4. Global Brain Disease by: Treatment Type (Value)
        • 7.2.4.1. Surgery
        • 7.2.4.2. Radiation Therapy
        • 7.2.4.3. Targeted Therapy
        • 7.2.4.4. Chemotherapy
        • 7.2.4.5. Immunotherapy
      • 7.2.5. Global Brain Disease Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brain Disease: by Type(USD Million)
  • Table 2. Brain Disease Brain Cancer , by Region USD Million (2015-2020)
  • Table 3. Brain Disease Alzheimer Disease , by Region USD Million (2015-2020)
  • Table 4. Brain Disease Alcoholism , by Region USD Million (2015-2020)
  • Table 5. Brain Disease Amnesia , by Region USD Million (2015-2020)
  • Table 6. Brain Disease Epilepsy , by Region USD Million (2015-2020)
  • Table 7. Brain Disease Meningitis , by Region USD Million (2015-2020)
  • Table 8. Brain Disease Others , by Region USD Million (2015-2020)
  • Table 9. Brain Disease: by Distribution Channel(USD Million)
  • Table 10. Brain Disease Hospitals Pharmacy , by Region USD Million (2015-2020)
  • Table 11. Brain Disease Online Pharmacy , by Region USD Million (2015-2020)
  • Table 12. Brain Disease Offline Pharmacy , by Region USD Million (2015-2020)
  • Table 13. Brain Disease: by Diagnosis Type(USD Million)
  • Table 14. Brain Disease CT Scan , by Region USD Million (2015-2020)
  • Table 15. Brain Disease MRI , by Region USD Million (2015-2020)
  • Table 16. Brain Disease PET-CT Scan , by Region USD Million (2015-2020)
  • Table 17. Brain Disease Molecular Testing , by Region USD Million (2015-2020)
  • Table 18. Brain Disease EEG , by Region USD Million (2015-2020)
  • Table 19. Brain Disease Others , by Region USD Million (2015-2020)
  • Table 20. Brain Disease: by Treatment Type(USD Million)
  • Table 21. Brain Disease Surgery , by Region USD Million (2015-2020)
  • Table 22. Brain Disease Radiation Therapy , by Region USD Million (2015-2020)
  • Table 23. Brain Disease Targeted Therapy , by Region USD Million (2015-2020)
  • Table 24. Brain Disease Chemotherapy , by Region USD Million (2015-2020)
  • Table 25. Brain Disease Immunotherapy , by Region USD Million (2015-2020)
  • Table 26. South America Brain Disease, by Country USD Million (2015-2020)
  • Table 27. South America Brain Disease, by Type USD Million (2015-2020)
  • Table 28. South America Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 29. South America Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 30. South America Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 31. Brazil Brain Disease, by Type USD Million (2015-2020)
  • Table 32. Brazil Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 33. Brazil Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 34. Brazil Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 35. Argentina Brain Disease, by Type USD Million (2015-2020)
  • Table 36. Argentina Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 37. Argentina Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 38. Argentina Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 39. Rest of South America Brain Disease, by Type USD Million (2015-2020)
  • Table 40. Rest of South America Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 41. Rest of South America Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 42. Rest of South America Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 43. Asia Pacific Brain Disease, by Country USD Million (2015-2020)
  • Table 44. Asia Pacific Brain Disease, by Type USD Million (2015-2020)
  • Table 45. Asia Pacific Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 46. Asia Pacific Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 47. Asia Pacific Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 48. China Brain Disease, by Type USD Million (2015-2020)
  • Table 49. China Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 50. China Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 51. China Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 52. Japan Brain Disease, by Type USD Million (2015-2020)
  • Table 53. Japan Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 54. Japan Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 55. Japan Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 56. India Brain Disease, by Type USD Million (2015-2020)
  • Table 57. India Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 58. India Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 59. India Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 60. South Korea Brain Disease, by Type USD Million (2015-2020)
  • Table 61. South Korea Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 62. South Korea Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 63. South Korea Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 64. Taiwan Brain Disease, by Type USD Million (2015-2020)
  • Table 65. Taiwan Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 66. Taiwan Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 67. Taiwan Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 68. Australia Brain Disease, by Type USD Million (2015-2020)
  • Table 69. Australia Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 70. Australia Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 71. Australia Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Brain Disease, by Type USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 76. Europe Brain Disease, by Country USD Million (2015-2020)
  • Table 77. Europe Brain Disease, by Type USD Million (2015-2020)
  • Table 78. Europe Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 79. Europe Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 80. Europe Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 81. Germany Brain Disease, by Type USD Million (2015-2020)
  • Table 82. Germany Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 83. Germany Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 84. Germany Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 85. France Brain Disease, by Type USD Million (2015-2020)
  • Table 86. France Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 87. France Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 88. France Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 89. Italy Brain Disease, by Type USD Million (2015-2020)
  • Table 90. Italy Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 91. Italy Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 92. Italy Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 93. United Kingdom Brain Disease, by Type USD Million (2015-2020)
  • Table 94. United Kingdom Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 95. United Kingdom Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 96. United Kingdom Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 97. Netherlands Brain Disease, by Type USD Million (2015-2020)
  • Table 98. Netherlands Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 99. Netherlands Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 100. Netherlands Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 101. Rest of Europe Brain Disease, by Type USD Million (2015-2020)
  • Table 102. Rest of Europe Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 103. Rest of Europe Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 104. Rest of Europe Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 105. MEA Brain Disease, by Country USD Million (2015-2020)
  • Table 106. MEA Brain Disease, by Type USD Million (2015-2020)
  • Table 107. MEA Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 108. MEA Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 109. MEA Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 110. Middle East Brain Disease, by Type USD Million (2015-2020)
  • Table 111. Middle East Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 112. Middle East Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 113. Middle East Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 114. Africa Brain Disease, by Type USD Million (2015-2020)
  • Table 115. Africa Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 116. Africa Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 117. Africa Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 118. North America Brain Disease, by Country USD Million (2015-2020)
  • Table 119. North America Brain Disease, by Type USD Million (2015-2020)
  • Table 120. North America Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 121. North America Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 122. North America Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 123. United States Brain Disease, by Type USD Million (2015-2020)
  • Table 124. United States Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 125. United States Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 126. United States Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 127. Canada Brain Disease, by Type USD Million (2015-2020)
  • Table 128. Canada Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 129. Canada Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 130. Canada Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 131. Mexico Brain Disease, by Type USD Million (2015-2020)
  • Table 132. Mexico Brain Disease, by Distribution Channel USD Million (2015-2020)
  • Table 133. Mexico Brain Disease, by Diagnosis Type USD Million (2015-2020)
  • Table 134. Mexico Brain Disease, by Treatment Type USD Million (2015-2020)
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Brain Disease: by Type(USD Million)
  • Table 146. Brain Disease Brain Cancer , by Region USD Million (2021-2026)
  • Table 147. Brain Disease Alzheimer Disease , by Region USD Million (2021-2026)
  • Table 148. Brain Disease Alcoholism , by Region USD Million (2021-2026)
  • Table 149. Brain Disease Amnesia , by Region USD Million (2021-2026)
  • Table 150. Brain Disease Epilepsy , by Region USD Million (2021-2026)
  • Table 151. Brain Disease Meningitis , by Region USD Million (2021-2026)
  • Table 152. Brain Disease Others , by Region USD Million (2021-2026)
  • Table 153. Brain Disease: by Distribution Channel(USD Million)
  • Table 154. Brain Disease Hospitals Pharmacy , by Region USD Million (2021-2026)
  • Table 155. Brain Disease Online Pharmacy , by Region USD Million (2021-2026)
  • Table 156. Brain Disease Offline Pharmacy , by Region USD Million (2021-2026)
  • Table 157. Brain Disease: by Diagnosis Type(USD Million)
  • Table 158. Brain Disease CT Scan , by Region USD Million (2021-2026)
  • Table 159. Brain Disease MRI , by Region USD Million (2021-2026)
  • Table 160. Brain Disease PET-CT Scan , by Region USD Million (2021-2026)
  • Table 161. Brain Disease Molecular Testing , by Region USD Million (2021-2026)
  • Table 162. Brain Disease EEG , by Region USD Million (2021-2026)
  • Table 163. Brain Disease Others , by Region USD Million (2021-2026)
  • Table 164. Brain Disease: by Treatment Type(USD Million)
  • Table 165. Brain Disease Surgery , by Region USD Million (2021-2026)
  • Table 166. Brain Disease Radiation Therapy , by Region USD Million (2021-2026)
  • Table 167. Brain Disease Targeted Therapy , by Region USD Million (2021-2026)
  • Table 168. Brain Disease Chemotherapy , by Region USD Million (2021-2026)
  • Table 169. Brain Disease Immunotherapy , by Region USD Million (2021-2026)
  • Table 170. South America Brain Disease, by Country USD Million (2021-2026)
  • Table 171. South America Brain Disease, by Type USD Million (2021-2026)
  • Table 172. South America Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 173. South America Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 174. South America Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 175. Brazil Brain Disease, by Type USD Million (2021-2026)
  • Table 176. Brazil Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 177. Brazil Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 178. Brazil Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 179. Argentina Brain Disease, by Type USD Million (2021-2026)
  • Table 180. Argentina Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 181. Argentina Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 182. Argentina Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 183. Rest of South America Brain Disease, by Type USD Million (2021-2026)
  • Table 184. Rest of South America Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 185. Rest of South America Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 186. Rest of South America Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 187. Asia Pacific Brain Disease, by Country USD Million (2021-2026)
  • Table 188. Asia Pacific Brain Disease, by Type USD Million (2021-2026)
  • Table 189. Asia Pacific Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 190. Asia Pacific Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 191. Asia Pacific Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 192. China Brain Disease, by Type USD Million (2021-2026)
  • Table 193. China Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 194. China Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 195. China Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 196. Japan Brain Disease, by Type USD Million (2021-2026)
  • Table 197. Japan Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 198. Japan Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 199. Japan Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 200. India Brain Disease, by Type USD Million (2021-2026)
  • Table 201. India Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 202. India Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 203. India Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 204. South Korea Brain Disease, by Type USD Million (2021-2026)
  • Table 205. South Korea Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 206. South Korea Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 207. South Korea Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 208. Taiwan Brain Disease, by Type USD Million (2021-2026)
  • Table 209. Taiwan Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 210. Taiwan Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 211. Taiwan Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 212. Australia Brain Disease, by Type USD Million (2021-2026)
  • Table 213. Australia Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 214. Australia Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 215. Australia Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 216. Rest of Asia-Pacific Brain Disease, by Type USD Million (2021-2026)
  • Table 217. Rest of Asia-Pacific Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 218. Rest of Asia-Pacific Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 219. Rest of Asia-Pacific Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 220. Europe Brain Disease, by Country USD Million (2021-2026)
  • Table 221. Europe Brain Disease, by Type USD Million (2021-2026)
  • Table 222. Europe Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 223. Europe Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 224. Europe Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 225. Germany Brain Disease, by Type USD Million (2021-2026)
  • Table 226. Germany Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 227. Germany Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 228. Germany Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 229. France Brain Disease, by Type USD Million (2021-2026)
  • Table 230. France Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 231. France Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 232. France Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 233. Italy Brain Disease, by Type USD Million (2021-2026)
  • Table 234. Italy Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 235. Italy Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 236. Italy Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 237. United Kingdom Brain Disease, by Type USD Million (2021-2026)
  • Table 238. United Kingdom Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 239. United Kingdom Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 240. United Kingdom Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 241. Netherlands Brain Disease, by Type USD Million (2021-2026)
  • Table 242. Netherlands Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 243. Netherlands Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 244. Netherlands Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 245. Rest of Europe Brain Disease, by Type USD Million (2021-2026)
  • Table 246. Rest of Europe Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 247. Rest of Europe Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 248. Rest of Europe Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 249. MEA Brain Disease, by Country USD Million (2021-2026)
  • Table 250. MEA Brain Disease, by Type USD Million (2021-2026)
  • Table 251. MEA Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 252. MEA Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 253. MEA Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 254. Middle East Brain Disease, by Type USD Million (2021-2026)
  • Table 255. Middle East Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 256. Middle East Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 257. Middle East Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 258. Africa Brain Disease, by Type USD Million (2021-2026)
  • Table 259. Africa Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 260. Africa Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 261. Africa Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 262. North America Brain Disease, by Country USD Million (2021-2026)
  • Table 263. North America Brain Disease, by Type USD Million (2021-2026)
  • Table 264. North America Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 265. North America Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 266. North America Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 267. United States Brain Disease, by Type USD Million (2021-2026)
  • Table 268. United States Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 269. United States Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 270. United States Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 271. Canada Brain Disease, by Type USD Million (2021-2026)
  • Table 272. Canada Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 273. Canada Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 274. Canada Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 275. Mexico Brain Disease, by Type USD Million (2021-2026)
  • Table 276. Mexico Brain Disease, by Distribution Channel USD Million (2021-2026)
  • Table 277. Mexico Brain Disease, by Diagnosis Type USD Million (2021-2026)
  • Table 278. Mexico Brain Disease, by Treatment Type USD Million (2021-2026)
  • Table 279. Research Programs/Design for This Report
  • Table 280. Key Data Information from Secondary Sources
  • Table 281. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brain Disease: by Type USD Million (2015-2020)
  • Figure 5. Global Brain Disease: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Brain Disease: by Diagnosis Type USD Million (2015-2020)
  • Figure 7. Global Brain Disease: by Treatment Type USD Million (2015-2020)
  • Figure 8. South America Brain Disease Share (%), by Country
  • Figure 9. Asia Pacific Brain Disease Share (%), by Country
  • Figure 10. Europe Brain Disease Share (%), by Country
  • Figure 11. MEA Brain Disease Share (%), by Country
  • Figure 12. North America Brain Disease Share (%), by Country
  • Figure 13. Global Brain Disease share by Players 2020 (%)
  • Figure 14. Global Brain Disease share by Players (Top 3) 2020(%)
  • Figure 15. Global Brain Disease share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 20. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 21. F. Hoffmann La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. F. Hoffmann La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 23. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 24. GE Healthcare (United States) Revenue: by Geography 2020
  • Figure 25. Abbvie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbvie Inc. (United States) Revenue: by Geography 2020
  • Figure 27. AC Immune SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. AC Immune SA (Switzerland) Revenue: by Geography 2020
  • Figure 29. Allergan PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Allergan PLC (Ireland) Revenue: by Geography 2020
  • Figure 31. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co (United States) Revenue: by Geography 2020
  • Figure 33. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 35. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 37. Global Brain Disease: by Type USD Million (2021-2026)
  • Figure 38. Global Brain Disease: by Distribution Channel USD Million (2021-2026)
  • Figure 39. Global Brain Disease: by Diagnosis Type USD Million (2021-2026)
  • Figure 40. Global Brain Disease: by Treatment Type USD Million (2021-2026)
  • Figure 41. South America Brain Disease Share (%), by Country
  • Figure 42. Asia Pacific Brain Disease Share (%), by Country
  • Figure 43. Europe Brain Disease Share (%), by Country
  • Figure 44. MEA Brain Disease Share (%), by Country
  • Figure 45. North America Brain Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Eli Lilly (United States)
  • F. Hoffmann La Roche AG (Switzerland)
  • GE Healthcare (United States)
  • Abbvie Inc. (United States)
  • AC Immune SA (Switzerland)
  • Allergan PLC (Ireland)
  • Merck & Co (United States)
  • Novartis AG (Switzerland)
  • AstraZeneca plc (United Kingdom)
Additional players considered in the study are as follows:
Medtronic, Inc. (Ireland) , Boston Scientific Corporation (United States) , Delmar Pharmaceuticals Inc. (United States) , Omeros Corporation (United States)
Select User Access Type

Key Highlights of Report


Jul 2021 210 Pages 61 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Brain Disease Market are Pfizer Inc. (United States), Eli Lilly (United States), F. Hoffmann La Roche AG (Switzerland), GE Healthcare (United States), Abbvie Inc. (United States), AC Immune SA (Switzerland), Allergan PLC (Ireland), Merck & Co (United States), Novartis AG (Switzerland) and AstraZeneca plc (United Kingdom) etc.
Brain disease is a type of central nervous system diseases. It refers to disabilities that affect the brain. There are various disability condition present in the brain disease such as brain deterioration, neurodegenerative diseases such as Alzheimer’s, Huntington’s disease and others. There are various symptoms of brain diseases such as headache, memory loss, tremors, increased reflexes, slurred speech, paralysis, and inability to concentrate among others. Surgery, radiation therapy, targeted therapy, chemotherapy and immunotherapy are the various treatment types used for brain disease.

Know More About Global Brain Disease Market Report?